Insmed (INSM) announced positive topline results from an Aspen Phase 3 study of Brensocatib. Insmed is a biopharmaceutical company that develops therapies for patients with serious and rare diseases. CEO Will Lewis joins Nicole Petallides to give an overview of the company as Insmed completed a $650M public offering on Friday. He talks about the company’s current product pipeline. Tune in to find out more about the stock market today.
The Watch List
04 Jun 2024
SHARE